CRSP (CRISPR Therapeutics Corp) Total Business Assets

Official company branding of CRISPR Therapeutics Corp (CRSP)

Complex cryo-logistics ensure the preservation of CRISPR Therapeutics AG (CRSP) drugs. The foundation of success is rooted in the culture of a leading research institute, where top biologists implement bold DNA editing hypotheses. The valuation of controlled resources in GURU.Markets is shown on a line chart containing data where the indicator remains at 2339.94. High barriers to entry and patent protection create a reliable shield against new market players.

CRSP - CRISPR Therapeutics AG Company Total Assets over the range 07/04/2022 - 11/01/2026

Analytical breakdowns and data insights for company CRISPR Therapeutics Corp (CRSP)

- current price and projected stock value:
Quote Chart crisprtx.com|CRSP - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization CRISPR|CRSP - Total Company Value
- book capitalization information:
Equity per Share CRISPR Therapeutics|CRSP - Book Capitalization|Market Capitalization to Book Value Ratio crisprtx.com|CRSP - Company Total Assets
- debt and liquidity details:
Total Debt to Equity Ratio CRISPR Therapeutics AG|CRSP - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CRISPR|CRSP - Company Aggregate Debts|Debts to Net Assets CRISPR|CRSP - Company Long-Term Debt|Short-Term Debt Volume CRISPR Therapeutics|Critical Liquidity Ratio crisprtx.com
- earnings and market ratios statistics:
CRSP - Company Net Income
Fundamental valuation:CRSP - crisprtx.com
Core merchandise of CRISPR

To assess the issuer's credit quality, it is essential to analyze the combination of equity and debt obligations, which in this metric is calculated inversely via ROA. The asset growth trend confirms the financial stability of CRISPR Therapeutics AG (CRSP), bolstered by the commercialization of Casgevy therapy and the inflow of partner payments, which minimizes insolvency risk while preserving resources for the development of promising in-vivo platforms.

Main competitors

Total Asset Value of Company TEM (Tempus AI, Inc)|QGEN (Qiagen) - Company Total Assets|Total Business Assets IONS (Ionis Pharmaceuticals, Inc.)|Aggregate Company Assets Repligen Corp. (RGEN)|Avidity Corp - Total Business Assets|Company Total Assets WGS (GeneDx Holdings Corp.)|Company Total Assets ultragenyx.com RARE|Beam Therapeutics - Company Total Assets|Sarepta Therapeutics (SRPT) - Cumulative Company Assets|Twist Bio (TWST) - Aggregate Company Assets|10x - Aggregate Asset Value|NTLA (Intellia Therapeutics) - Company Total Assets|stoketherapeutics.com (STOK) - Company Total Asset Base|Aggregate Company Assets BioLife Solutions (BLFS)|Company Total Asset Base Wave Life Sciences Ltd|Aggregate Company Assets Maze Tx MAZE|SION (Sionna Corp) - Total Asset Value of Company|PRME - Aggregate Company Assets|Aggregate Asset Value TSHA (tayshagtx.com)|QURE (uniQure) - Cumulative Company Assets|MeiraGTx Holdings - Aggregate Asset Value|Cumulative Company Assets RGNX|SLDB (Solid Corp) - Aggregate Business Assets|Company Total Assets OCGN|PACB (pacb.com) - Aggregate Asset Value|Company Total Assets BNTC (Benitec Biopharma)|Design Therapeutics Inc (DSGN) - Company Assets|RCKT - Aggregate Company Assets|Aggregate Asset Value FDMT (4D Molecular Corp)|LXEO: Company Total Assets|Korro Bio (KRRO) - Company Total Assets|Aggregate Company Assets Editas Medicine|Silence Therapeutics PLC - Total Asset Value of Company|Company Total Assets PRQR|CDXS - Company Assets|Sangamo Therapeutics - Cumulative Company Assets|Company Total Assets Nautilus Biotechnology, Inc. NAUT|MGX: Cumulative Company Assets|precisionbiosciences.com - Aggregate Business Assets|GBIO: Company Total Assets|BOLD - Company Total Asset Base|XCUR (Exicure Inc.) - Company Total Assets|Cumulative Company Assets Celsion Corporation (IMNN)|Aggregate Company Assets Phio Pharmaceuticals (PHIO)|Company Total Asset Base mustangbio.com|TransCode Therapeutics, Inc. - Cumulative Company Assets|Aggregate Asset Value BNGO|Applied DNA Sciences - Company Total Assets|BLUE - Company Total Assets|IPA: Company Total Assets|Company Balance Sheet Assets Omega Therapeutics Inc OMGA|OMIC (Singular Genomics Systems Inc) - Company Total Assets|Cumulative Company Assets Regulus (RGLS)|Aggregate Company Assets Syros Pharmaceuticals (SYRS)|TBIO (telesisbio.com) - Aggregate Asset Value|Aggregate Company Assets TRACON Pharmaceuticals, Inc. TCON|Company Total Asset Base Unity Biotechnology Inc. (UBX)